19.05.2022 | Tracker

Product Launch Tracker: HCPs excited for BMS’ newly approved ‘Camzyos’

By Paul Cranston and Tomi Shobande

Every month, CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.


Throughout April 2022 we tracked the global conversations of 1,941 HCPs who posted 2,647 English-language Twitter posts about the launches and approvals of new products.

Chart showing HCP mentions of product launches on Twitter

Over the last month, HCPs discussed product approvals for the treatment of a variety of diseases including lymphoma, severe mental illness, and PIK3CA-related overgrowth spectrum. Additionally, in HCPs discussions regarding advances in diagnosing and treating COVID-19, a new ‘breathalyser’ style test for the disease gained attention. However, the approval that generated the most discussion among HCPs in April was a new oral heart disease treatment produced by Bristol Myers Squibb.

Towards the end of April the FDA approved Camzyos (mavacamten) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM). As a first-in-class treatment, many HCPs took to social media to share their positive sentiments towards the Bristol Myers Squibb product, describing it as a big day for the HCM community. 

Another product to gain approval was BioXcel Therapeutics dexmedetomidine (Iglami) sublingual film for the acute treatment of adult patients with agitation associated with schizophrenia or bipolar I or II disorder in adults. HCPs showed interest in the product, sharing the news of its approval, however some questioned whether agitated patients would be willing to take a sublingual preparation of the drug.

HCPs also shared the news of the FDA’s approval of Novartis’ Vijoice (alpelisib) for the treatment of patients with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systematic therapy. Vijoice is the first FDA approved treatment for PROS, a spectrum of rare conditions characterised by overgrowths and blood vessel anomalies affecting the quality of life of patients. HCPs described the approval as huge news for precision medicine

In the COVID-19 space, HCP discussion increased as the FDA authorised the emergency use of the InspectIR Breathalyser – the first COVID-19 diagnostic test uses breath samples rather than swab samples to detect the presence of the SARS-CoV 2 virus. When sharing the news of this approval HCPs highlighted its accuracy, which is higher than that of PCR testing, and also suggested it was a good alternative for those who don’t like swabbing their nose.

Finally, at the beginning of April, the FDA also approved Gilead’s Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients, as a second-line treatment for adults with large B-cell lymphoma. The news of this approval was met positively by HCPs, with it being described as excellent news for lymphoma patients.

The three most shared links from HCPs discussing product launches in April were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.


  • Using CREATION Pinpoint® the English-language Twitter conversations of HCPs globally discussing new pharmaceutical product launches and drug approvals between 1 April and 30 April 2022 were analysed in order to discover which new product launches HCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by HCPs in their Twitter conversations.
  • Between 1 April and 30 April 2022, there were 2,647 HCP mentions of new pharmaceutical product launches and drug approvals from 1,941 unique HCP authors from around the world.

View the latest and archived trackers here

View all articles >

Meet the Authors

Paul Cranston

Paul analyses the online conversations of HCPs to provide insights for pharmaceutical companies about what HCPs think. With a background in international development, he is passionate about using data to reveal the unmet needs in healthcare communities.

In his free time, Paul can often be found either writing songs on his guitar or kicking a ball around on a football field.

Tomi Shobande

Tomi is passionate about building relationships with clients and helping them attain their business goals and objectives. With a background in law, international development and human rights, she is keen on bringing about a positive difference around healthcare inequities and shaping health outcomes for all groups.

Tomi enjoys spending good quality time with friends and family. She also is passionate about travel and learning different cultures and histories along the way.

Suggested next

#WhatHCPsThink About Virtual Congress

18.06.2020 | Article

#WhatHCPsThink About Virtual Congress

#WhatHCPsThink About Virtual Congress

By Lara Meyer

24.08.2021 | Article

UK HCPs Debate The Comparisons Drawn Between COVID-19 And Other Viruses

UK HCPs Debate The Comparisons Drawn Between COVID-19 And Other Viruses

By Mark Sullivan

View all articles >